• PT-141 - Zion Pharma

PT-141 – preparation kit


PT-141 (Bremelanotide)
The kit includes:
  • a vial of powder 5 mg;
  • an atomizer with bacteriostatic water 5 ml (1% solution of benzyl alcohol in demiralized water);
  • a syringe;
  • a needle;
  • instructions for preparing the solution.

After dissolving, there is 0.138 mg of PT-141 per dose.

SKU: pt-141-5-mg


OTHER NAMES: bremelanotide; PT-141; Vyleesi

CAS NUMBER: 189691-06-3



ITEM TYPE: vial of powder, atomizer with bacteriostatic water, needle, syringe, instructions for preparing the solution

QUANTITY PER PACK: 5 milligrams


SUGGESTED USE: 0.138 mg to 0.276 mg

STORAGE: Store in the refrigerator at a temperature of 2 to 5 Celsius degrees.

WARNING: Keep out of reach of children. Do not take this or any other supplement if under the age of 18, pregnant or nursing a baby, or if you have any known or suspected medical conditions, and/or taking prescription drugs or over the counter medications.

DISCLAIMER: Always consult with a qualified health physician before taking any new dietary supplement. This product is not intended to diagnose, treat, cure, or prevent any diseases.

The product is not intended for human use. For laboratory use only.

PEPTIDES preparation instructions – pdf


Bremelanotide was approved by the FDA in June 2019 for the treatment of acquired, generalized HSDD in premenopausal women. Bremelanotide activates melanocortin receptors,but the mechanism by which it improves sexual desire is unknown. To use bremelanotide, women inject it under the skin ofthe abdomen or thigh at least 45 minutes before anticipated sexual activity. The optimal time to inject bremelanotide may vary based on the duration of benefit and side effects experienced. More than one dose of bremelanotide should not be used within 24 hours or more than eight doses per month. Common side effects include nausea, vomiting, flushing, injection site reactions, and headache. Bremelanotide should not be used in women with high blood pressure that is uncontrolled or in those with known cardiovascular disease, and it is not recommended for women at high risk for cardiovascular disease. The safety and efficacy of bremelanotide has not been studied in breast cancer survivors, and there are no recommendations regarding its use in this population.


Treatment of sexual dysfunction (melanocortin receptor agonist). Bremelanotide is used to treat low sexual desire in women who have not gone through menopause and have not had low sexual desire in the past. Bremelanotide should be used only to treat low sexual desire that occurs with any type of sexual activity, in any sexual situation, or with any sexual partner. Bremelanotide should not be used to treat low sexual desire that is caused by relationship problems, health problems, mental illness, or by using certain drugs or medications.

Clinical Use

Bremelanotide, or PT-141, is a synthetic, central melanocortin receptor agonist that increases αmelanocyte stimulating hormone (α-MSH) in the body. It has been reported to aid in sexual experiences for men and women. PT-141 is a deaminated derivative and likely metabolite of Melanotan II, another synthetic melanocortin receptor agonist initially used for tanning purposes. During treatment with Melanotan II, researchers, clinicians and patients noticed an increase in sexual activity. However, Side effects reported with melanotan II include nausea, vomiting, yawning, and a delayed onset of erection (approximately 2 hours). So researchers began to look for alternatives to melanotan II, and bremelanotide was synthesized in 2000 and trials began.Unlike the FDA approved PDE5 inhibitors that improved sexual function by improving nitric oxide and vascular function, PT-141 works on the CNS, thus eliciting a more desirous sexual response. Of the 5 meanocortin receptors (1-5), PT-141 has the highest affinity for melanocortin receptor 4 (MC4R). In the hypothalamus, α-MSH suppresses appetite (MC4R receptor), with MC4R defects are reported to be a cause for autosomal dominant obesity, accounting for approximately 6% of all cases of early onset obesity. MC4R stimulation also contributes to improved sexual function in both men (improving penile erections) and women (increasing desire and arousal).